WVU cancer researcher and Assistant Professor of Pharmaceutical Sciences Wei Du, MD, PhD, teamed up with researchers from Cincinnati Children’s Hospital Medical Center to focus on improving outcomes and reducing side effects of traditional stem cell transplant. Their work was recently published in Leukemia, one of the top journals in hematology.
The studies identify an innovative drug that targets Cdc42, a member of one of the Rho GTPase family, which increases bone marrow accessibility and therefore improves stem cell transplant outcome. This project is an extension of previous research in the field of Rho GTPase family in hematopoiesis and is intended to address the urgent and important need for stem cell transplantation. Dr. Du’s work offers a novel preparative regimen for stem cell transplantation in treating bone marrow failure and other blood diseases. They are currently working on establishing improved methods for blood stem cell harvest and transplantation that could significantly impact future stem cell therapies for patients with leukemia and other blood cancers.
In the News:
Two Studies Describe Improved Approach to Bone Marrow Transplant - Cincinnati Children's Newsroom
WVU's Office of Health Services Research partnering with Cancer Institute on cervical cancer prevention project
The WVU School of Public Health's Office of Health Services Research is partnering with Stephenie Kennedy-Rea, Ed.D., and the WVU Cancer Institute in a new, five-year effort funded by the National Cancer Institute to reduce health disparities in cervical cancer in Appalachia.
Mark your calendars for an upcoming WVU Health Sciences Center Campus Conversation on campus culture on Tue., June 18 at noon in Room 1905 at the Health Sciences Center.
Employees and covered spouses enrolled on a WVU Medicine medical plan must: 1) Complete the RealAge Test®, 2) Receive a Preventive Exam & 3) Indicate Tobacco Status through mycare.sharecare.com by 10/31/19.